Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKACA | P17612 | 13/20 | 1.00 |
| ▸ | PRKACG | P22612 | 13/20 | 1.00 |
| ▸ | PRKACB | P22694 | 13/20 | 1.00 |
| ▸ | PRKCA | P17252 | 5/20 | 1.00 |
| ▸ | CDK4 | P11802 | 4/20 | 1.00 |
| ▸ | CCND1 | P24385 | 4/20 | 1.00 |
| ▸ | PRKCB | P05771 | 4/20 | 1.00 |
| ▸ | PRKCH | P24723 | 3/20 | 1.00 |
| ▸ | PRKCQ | Q04759 | 3/20 | 1.00 |
| ▸ | PRKCD | Q05655 | 3/20 | 1.00 |
| ▸ | PRKCE | Q02156 | 3/20 | 1.00 |
| ▸ | CCNB2 | O95067 | 3/20 | 1.00 |
| ▸ | CDK1 | P06493 | 3/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 3/20 | 1.00 |
| ▸ | CCNB3 | Q8WWL7 | 3/20 | 1.00 |
| ▸ | PRKD1 | Q15139 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | PIM1 | P11309 | 2/20 | 1.00 |
| ▸ | GSK3B | P49841 | 2/20 | 1.00 |
| ▸ | CCNE2 | O96020 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gf-109203 SCHEMBL29353725 | 1.00 | PRKACA (1.00) | PRKACAPRKACGPRKACBPRKCACDK4 | |
| Gf-109203 SCHEMBL29534077 | 0.99 | PRKACA (0.98) | PRKACAPRKACGPRKACBPRKCACDK4 | |
| Gf-109203 SCHEMBL1199513 | 0.99 | PRKACA (0.98) | PRKACAPRKACGPRKACBPRKCACDK4 | |
| SCHEMBL7823516 | 0.94 | PRKACA (0.88) | PRKACAPRKACGPRKACBPRKCACDK4 | |
| SCHEMBL14022587 | 0.92 | PRKACA (0.85) | PRKACAPRKACGPRKACBPRKCACDK4 | |
| SCHEMBL9086320 | 0.90 | PRKACA (0.82) | PRKACAPRKACGPRKACBPRKCACDK4 | |
| SCHEMBL9087076 | 0.90 | PRKACA (0.82) | PRKACAPRKACGPRKACBPRKCACDK4 | |
| SCHEMBL9087451 | 0.90 | PRKACA (0.82) | PRKACAPRKACGPRKACBPRKCACDK4 | |
| SCHEMBL7826095 | 0.90 | PRKACA (0.81) | PRKACAPRKACGPRKACBPRKCACDK4 | |
| SCHEMBL7815621 | 0.90 | PRKACA (0.81) | PRKACAPRKACGPRKACBPRKCACDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 304 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2797596-B1 | PERITONEAL DIALYSIS FLUID COMPRISING A GSK-3 INHIBITOR | ZYTOPROTEC GMBH (AT) | 2019-06-26 | — | — | EP | claimed |
| US-20150004255-A1 | PERITONEAL DIALYSIS FLUID COMPRISING A GSK-3 INHIBITOR | ZYTOPROTEC GMBH (AT) | 2015-01-01 | — | — | US | claimed |
| CN-104023722-A | Peritoneal dialysis fluid comprising GSK-3 inhibitor | ZYTOPROTEC GMBH | 2014-09-03 | — | — | CN | claimed |
| WO-2014081922-A1 | COMPOSITIONS AND METHODS USEFUL IN PREVENTING AND TREATING APICOMPLEXA INFECTIONS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2014-05-30 | — | — | WO | claimed |
| EP-2653166-A2 | Pharmaceutical composition and related methods | Healor Ltd. (IL) | 2013-10-23 | — | — | EP | claimed |
| EP-2609918-A1 | Peritoneal dialysis fluid comprising a GSK-3 inhibitor | Zytoprotec GmbH (AT) | 2013-07-03 | — | — | EP | claimed |
| CN-102755649-A | Pharmaceutical composition and related methods | HEALOR LTD | 2012-10-31 | — | — | CN | claimed |
| US-20120238019-A1 | STEM CELL CULTURE MEDIA FOR MAINTAINING STEMNESS OR INDUCING DIFFERENTIATION OF STEM CELLS | COLLEGE OF MEDICINE POCHON CHA UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2012-09-20 | — | — | US | claimed |
| EP-2494865-A2 | GUT FLORA-DERIVED EXTRACELLULAR VESICLES, AND METHOD FOR SEARCHING FOR A DISEASE MODEL, VACCINE, AND CANDIDATE DRUG AND FOR DIAGNOSIS USING SAME | Aeon Medix Inc. (KR) | 2012-09-05 | — | — | EP | claimed |
| US-20100310542-A1 | Pharmaceutical Compositions for treating wouds and related methods | HEALOR LTD. (IL) | 2010-12-09 | — | — | US | claimed |
| EP-2185184-A2 | PHARMACEUTICAL COMPOSITION FOR TREATING WOUNDS AND RELATED METHODS | HealOr Ltd. (IL) | 2010-05-19 | — | — | EP | claimed |
| WO-2009016629-A2 | PHARMACEUTICAL COMPOSITION FOR TREATING WOUNDS AND RELATED METHODS | HEALOR LTD. (IL) | 2009-02-05 | — | — | WO | claimed |
| US-20080009511-A1 | Cancer treatment with compounds inhibiting PKC alpha | LU ZHIMIN | 2008-01-10 | — | — | US | claimed |
| US-20070196514-A1 | Prostate cancer treatment with glycogen synthase kinase-3beta inhibitors | UNIVERSITY OF KANSAS MEDICAL CENTER | 2007-08-23 | — | — | US | claimed |
| US-20060099568-A1 | Signals and molecular species involved in senescence | SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) | 2006-05-11 | — | — | US | claimed |
| US-20060009492-A1 | Cancer treatment with compounds inhibiting PKC alpha | LU ZHIMIN | 2006-01-12 | — | — | US | claimed |
| WO-2003104482-A1 | SIGNALS AND MOLECULAR SPECIES INVOLVED IN SENESCENCE | METABOLIC ENGINEERING LABORATORIES CO., LTD. (KR) | 2003-12-18 | — | — | WO | claimed |
| EP-0397060-B1 | Maleinimide derivatives and their use as medicines | GOEDECKE AG (DE) | 2001-11-21 | — | — | EP | claimed |
| EP-4678737-A1 | METHOD FOR PRODUCING PRIMED PLURIPOTENT STEM CELLS | Kyoto University (JP) | 2026-01-14 | — | — | EP | disclosed |
| US-5380746-A | Bis-(1H-indol-3-YL)-maleinimide derivatives, processes for the preparation thereof and pharmaceutical compositions containing them | GOEDECKE AKTIENGESELLSCHAFT (DE) | 1995-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100310542-A1 | Pharmaceutical Compositions for treating wouds and related methods | PRKCZ, PRKCB, PRKCA | PRKACA 9/4885PRKACG 15/4885PRKACB 14/4885 |
| US-20080009511-A1 | Cancer treatment with compounds inhibiting PKC alpha | PRKCE, ROCK1, PRKCA | PRKACA 15/4885PRKACG 36/4885PRKACB 32/4885 |
| US-20060009492-A1 | Cancer treatment with compounds inhibiting PKC alpha | PRKCE, ROCK1, PRKCA | PRKACA 15/4885PRKACG 36/4885PRKACB 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.